265results about How to "Highly specific" patented technology

The present invention provides methods of directly stimulating neural tissue with optical energy. By stimulating neural tissue at wavelengths, laser pulses, and spot sizes disclosed herein, nerve stimulation may be used to uniquely stimulate neural tissue in way not afforded by other means of stimulation. It can allow basic scientists to study the properties of individual neurons or populations of neurons without piercing tissue with fragile microelectrodes. Furthermore, responses of neural tissue can be studied in a pure fashion without contamination by electrical artifact commonly seen with electrical stimulation. With respect to clinical uses, optical stimulation can be used to map function in subsections of peripheral nerves as an aid to operative repair. Finally, stimulation with optical energy does not require physical contact with the nerve which may be an advantage clinically when physical manipulation of neural tissue is not desired.

Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

Synthetic nano-sized crystalline calcium phosphate, particularly hydroxyapatite, having a specific surface area in the range of 150 m²/g to 300 m²/g, is described. The nano-sized crystalline calcium phosphate may be in the form of a powder or in the form of a coating on a surface. A method of producing a nano-sized crystalline calcium phosphate powder or coating is also described. The method comprises formation of a liquid crystalline phase in a water solution of calcium, phosphor and a surfactant, placing the phase in an ammonia atmosphere so that nano-sized crystals are formed, followed by either removal of the surfactant with a solvent and recovering the nano-sized crystals to obtain the powder, or diluting the ammonia-treated liquid crystalline phase with a hydrophobic organic solvent to create a microemulsion of the nano-sized crystals in water, dipping an oxide layer-coated surface of an object into the microemulsion, or alternatively saving the step of ammonia treatment of the liquid crystalline phase until after the dipping of the surface of an object into the microemulsion, followed by removal of the organic solvent and the surfactant from the surface to obtain the coating.

The invention provides methods of coupling protein ligands to a solid support. The invention also provides affinity chromatography matrices and methods of using affinity chromatography matrices to purify a target molecule.

A method and solution for perioperatively inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes multiple pain and inflammation inhibitory at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain and inflammation includes a serotonin2 antagonist, a serotonin3 antagonist, a histamine antagonist, a serotonin agonist, a cyclooxygenase inhibitor, a neurokinin1 antagonist, a neurokinin2 antagonist, a purinoceptor antagonist, an ATP-sensitive potassium channel opener, a calcium channel antagonist, a bradykinin1 antagonist, a bradykinin2 antagonist and a mu -opioid agonist.

A system, method, and computer program product for detecting variants from sequencing data. Aligned sequencing data can be provided and filters can be applied to the aligned sequencing data. The filtered data can be used as input, and a first classifier can be applied to determine if any alteration is present beyond an expected threshold due to a sequencing error and candidate variants can be identified. The identified candidate variants can be passed through additional filters to remove false positives. A somatic status of the filtered candidate variants can be determined using a second classifier. The related apparatus, systems, techniques and articles are also described.

Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

A front electronic equipment system includes a load electrical parts provided at a front portion of a vehicle, a front electrical control unit which receives a control signal for controlling the drive of the load electrical parts through a main bus line of the vehicle, and a drive control unit connected to the front electrical control unit through a sub bus line, converting the control signal into a drive signal, and driving the load electrical parts based on the drive signal. The front electrical control unit converts a communication protocol of the control signal from a communication protocol of the main bus line into a communication protocol of the sub bus line, and transmits the converted control signal received through the main bus line to the drive control unit through the sub bus line.

The invention relates to methods and compositions for identifying specific bacterial species, which are sulfur and iron oxidizers and/or reducers, from wall board (e.g., dry wall) and/or a patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the bacterial species from the wall board and/or the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the bacterial species, and specifically identifying the bacterial species. Kits and nucleic acids for use in the methods are also provided. Methods for eliminating the sulfur and iron oxidizing and/or reducing bacteria from wall board using a zeolite are also provided.

Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.